Trial Profile
Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 28 Dec 2015 New trial record